Vaccine giant Serum Institute of India considers plants in SA, Rwanda
CEO Adar Poonawalla says in Davos interview ‘there’s never been a better time to be a vaccine manufacturer’
23 May 2022 - 21:01
byAditya Kalra
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
A nurse displays a vial of Covishield, the AstraZeneca Covid-19 vaccine. Picture: REUTERS/FRANCIS MASCARENHAS
Davos — The Serum Institute of India (SII), the world’s biggest vaccine maker, is considering setting up its first manufacturing plant in Africa as it looks to expand globally after its success in selling Covid-19 shots, CEO Adar Poonawalla said on Monday.
“It’s never been a better time to be a vaccine manufacturer. I'm looking at expanding our manufacturing across the globe,” SII CEO Adar Poonawalla said during an interview at the World Economic Forum in Davos.
“There are some great countries out there: SA, Rwanda, you know, to name a few that we're looking at.”
Poonawalla said he was meeting some African officials in Davos to discuss his plans. Asked about possible investments, he said such projects typically required at least about $300m.
He did not say what products an African plant might make. Apart from Covid-19 shots, the SII’s Indian plants make vaccines for diphtheria, BCG, measles, rubella and other conditions.
SA-based Aspen Pharmacare said recently that it may have to switch its vaccine production lines to anaesthetics due to lack of orders, and state-backed vaccine manufacturer Biovac also faces uncertain demand.
Asked about concerns over the rise of monkeypox cases, Poonawalla said he believed the disease was not so infectious.
“We’ll wait and see even if we want to make a vaccine for it,” he said.
Monkeypox is usually mild and is endemic in parts of west and central Africa. The World Health Organization has said it expects to identify more cases as it expands surveillance in countries where the disease is not typically found.
On Covid-19, the SII has sold more than 1.5-billion doses in India of the AstraZeneca shot it makes and brands Covishield, and exported millions more.
But as demand has now waned, the company is putting its Indian Covishield facilities on standby and will “not produce anything there”, Poonawalla said, while adding it could resume output if needed.
The SII has also pulled the plug on a plan to produce and sell about 300-million doses of Russia's Sputnik Light Covid-19 vaccine. However, it is still making millions of doses of a version of the Novavax shot for India and other countries, Poonawalla said.
He estimated privately held SII was now valued at roughly $20bn, but said there was no immediate plan to go public.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Vaccine giant Serum Institute of India considers plants in SA, Rwanda
CEO Adar Poonawalla says in Davos interview ‘there’s never been a better time to be a vaccine manufacturer’
Davos — The Serum Institute of India (SII), the world’s biggest vaccine maker, is considering setting up its first manufacturing plant in Africa as it looks to expand globally after its success in selling Covid-19 shots, CEO Adar Poonawalla said on Monday.
“It’s never been a better time to be a vaccine manufacturer. I'm looking at expanding our manufacturing across the globe,” SII CEO Adar Poonawalla said during an interview at the World Economic Forum in Davos.
“There are some great countries out there: SA, Rwanda, you know, to name a few that we're looking at.”
Poonawalla said he was meeting some African officials in Davos to discuss his plans. Asked about possible investments, he said such projects typically required at least about $300m.
He did not say what products an African plant might make. Apart from Covid-19 shots, the SII’s Indian plants make vaccines for diphtheria, BCG, measles, rubella and other conditions.
SA-based Aspen Pharmacare said recently that it may have to switch its vaccine production lines to anaesthetics due to lack of orders, and state-backed vaccine manufacturer Biovac also faces uncertain demand.
Asked about concerns over the rise of monkeypox cases, Poonawalla said he believed the disease was not so infectious.
“We’ll wait and see even if we want to make a vaccine for it,” he said.
Monkeypox is usually mild and is endemic in parts of west and central Africa. The World Health Organization has said it expects to identify more cases as it expands surveillance in countries where the disease is not typically found.
On Covid-19, the SII has sold more than 1.5-billion doses in India of the AstraZeneca shot it makes and brands Covishield, and exported millions more.
But as demand has now waned, the company is putting its Indian Covishield facilities on standby and will “not produce anything there”, Poonawalla said, while adding it could resume output if needed.
The SII has also pulled the plug on a plan to produce and sell about 300-million doses of Russia's Sputnik Light Covid-19 vaccine. However, it is still making millions of doses of a version of the Novavax shot for India and other countries, Poonawalla said.
He estimated privately held SII was now valued at roughly $20bn, but said there was no immediate plan to go public.
Reuters
What will become of SA’s vaccine makers after Aspen’s failure?
AU calls on international agencies to support African vaccine manufacturers
Ramaphosa calls on international agencies to order African Covid-19 jabs
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Short shelf life of AstraZeneca’s vaccine hurts Covax rollout
How India’s vaccine milestone hides a divide
India to resume vaccine exports to poor countries in Covax programme
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.